30 Fisher 2 t 結果 FIM 3 FIM ADL 考察 FIM ADL ADL ADL 結論 ADL 50 FIM ADL FIM 今後の展望 ADL 30 ADL ADL 1 FIM
|
|
- あおい わかはら
- 7 years ago
- Views:
Transcription
1 29 大学院博士論文要旨 FIM? 櫻井 宏明 はじめに FIM Functional Independence Measure FIM ADL Activities of Daily Living FIM ADL ADL 目的 FIM 方法 ADL FIM 3 FIM FIM Tukeykramer
2 30 Fisher 2 t 結果 FIM 3 FIM ADL 考察 FIM ADL ADL ADL 結論 ADL 50 FIM ADL FIM 今後の展望 ADL 30 ADL ADL 1 FIM
3 31 大学院修士論文要旨 伊藤 和寛 はじめに 目的
4 32 ADL 2 3 方法 Brunnstrom Recovery Stage B.R.S 結果 6 考察 結論 6
5 33 大学院修士論文要旨 大森 亮哉 はじめに 方 法 目的 2 NPO
6 34 結果 考察 結論
7 35 大学院修士論文要旨 川村 和之 はじめに 目的 方法 BMI cm kg Spinal Mouse Index 3 MyLab25 3 mm kg mm/ kg 3 1SD 1SD 1SD +1SD Tukey-Kramer Spearman PASW-18 5% 結果 Spinal Mouse
8 36 SD SD SD mm/kg p 0.05 r = 0.39 p 0.05 r = 0.84 p 0.05 考察 3 3 r = 0.84 p 0.05 r = 0.39 p
9 37 結論
10 38 大学院修士論文要旨 栗本由美 はじめに 目 的 QOL QOL 方法 nose clip 2
11 39 10ml Mylab25 3.5MHz B-Mode M-mode 10 cm msec Scheffe 5% 結果 ICC msec msec msec msec p p 0.05 p 0.01 p 0.01 p 0.01 r = 0.90 r = 0.87 p 0.01 r = 0.65 p 0.05 r = 0.81 p 0.01 r = 0.66p 0.05 r = 0.65 p 0.05 考察 30
12 40 結論
13 41 大学院修士論文要旨 竹上 晴規 はじめに 目的 3 RI 3 方法 1 PTA RI 結果 PTA ml/min ml/min p 0.01 PTA cm/sec cm/sec p 0.01 PTA
14 PTA ns: 11 PTA ml/min ml/min p 0.01 PTA cm/sec cm/sec ns PTA p 0.05 考察 , 結語 3 MDCTA 3 3
15 43 大学院修士論文要旨 2 伊達 聡晃 はじめに 方 法 2009 AVATAR 3 3D 3D 3DDVD 3DS PS3 3D 3D 3D 3D 3 AVATAR 3D 2D 1.75m 3D ARK-900 NIDEK 目 的 結 果 3D 3D 3D 3D 2D 2 3D 2 2D 3D D 2D 3D
16 44 考察 Q D
17 45 大学院修士論文要旨 仲 賢一郎 序論 対象 方法 MOVE - tr/3d ( ) F -
18 W 2 H = H/W t p F Bonferroni Tukey-Kramer 1 結果 考察 結論 将来展望
19 47 MRI
20 48 大学院修士論文要旨 中尾はる香 はじめに 方 法 2 KK-Ay GLUT4 2 KK-Ay ddy ddy 2 KK- Ay 18 ddy KK-Ay mg/ kg 30 2g/kg ddy KK-Ay mg/kg 30 10mM ph7.0 KK-Ay 40mM 500μl ddy 40mM 500μl 20μl Craven p- -β -D- 3.0unit μg/ml p- 50% IC 50
21 49 結 果 考 察 1 KK-Ay KK-Ay 30mg/ kg mg/kg ddy 100mg/kg KK-Ay KK-Ay 30mg/kg 50% 100mg/kg ddy 100mg/kg 3 IC μg/ml % 50% 9 12g 30mg/kg 結論
22 50 大学院修士論文要旨 C X 永野 敬資 序論 CCl 4 C VC VC 目的 C X C 方法 ICR 6 30g X C mg/kg BW C 0.9%NaCl mmol/kg BW Gy 4Gy X X % AST ALT
23 51 TBARS Non-protein-SH NP-SH 結果 1 X 2Gy NP-SH X X VC(-) CCl 4 (-) VC(+) CCl 4 (-) X VC(-) CCl 4 (+) X X VC(-) CCl 4 (+) X VC(+) CCl 4 (-) X X VC(+) CCl 4 (-) 2 X 4Gy NP-SH X X VC(-) CCl 4 (-) VC(-) CCl 4 (+) VC(+) CCl 4 (-) VC(+) CCl 4 (+) X VC(-) CCl 4 (-) X X VC(-) CCl 4 (-) X VC(+) CCl 4 (-) X X VC(+) CCl 4 (-) 3 X 2Gy TBARS X VC(-) CCl 4 (-) VC(+) CCl 4 (+) X VC(-) CCl 4 (+) X X VC(-) CCl 4 (+) X VC(+) CCl 4 (-) X X VC(+) CCl 4 (-) 4 X 4Gy TBARS X X VC(-) CCl 4 (-) VC(+) CCl 4 (-) X X X VC(-) CCl 4 (-) X VC(+) CCl 4 (-) X VC(+) CCl 4 (-) X X VC(+) CCl 4 (-) X VC(+) CCl 4 (+) X X VC(+) CCl 4 (+) 考察 X TBARS X C X C X 結論 X C X
24 52 大学院修士論文要旨 2 8 水谷 真康 はじめに 2 Lohmann H 2010 Arm Cranking Exercise ACE ACE 目的 ACE 方法 HemoglobinA 1c HbA 1c 6.5% Exercise EX 8 8 Control CN 8 Follow FL ACE ergo meter strengthergo240 EM HbA 1c Ramp Anaerobic Threshold oxygen uptake AT-VO 2 Heart rate AT-HR Watt AT-Watt Body Mass Index BMI CN EX FL 4 EM Arm curl test EX 2 Problem Areas In Diabetes Survey PAID ACE EM EX AT-HR 90%
25 53 24 HbA 1c AT-VO 2 AT-HR AT-Watt BMI Bonferroni Arm curl test t PAID Wilcoxon t Bonferroni SPSS-18 5% 結 果 HbA 1c % CN EX p 0.05 FL mg/dl AT-VO 2 ml/kg/min AT-HR bpm AT-Watt Watt EX p 0.01 kcal p p 0.05 kg BMI kg/m2 kg Arm curl test 30 p 0.05 PAID score p p 0.05 p 0.05 p Cronbach 考 察 HbA1c CN EX HbA1c 0.4 FL ACE Boulé NG 8 HbA 1c 0.66% 0.4% ACE AT-Watt EX AT-VO 2 EX p 0.1 AT-HR Groot r 0.68 AT-VO 2 AT-Watt BMI Lehmann R
26 54 Arm curl test PAID 3 結言 ACE
27 55 大学院修士論文要旨 5 安江 一修 はじめに Ulcerative Colitis UC 1 3, , Granulocytapheresis GCAP QOL UC GCAP GCAP GCAP 目的 GCAP 5 方法 UC DAI Disease Activity Index Mayo mL/ min ,800mL 1 1
28 56 結果 考察 5 GCAP DAI mmHg 2 100mmHg 結論 5 GCAP 5 5
29 57 大学院修士論文要旨 山口 聡一郎 はじめに 目 的 方法
30 58 結 果 考 察 結論
31 59 大学院修士論文要旨 相田 和久 はじめに IT PACS PACS PACS WAN PACS 目的 PACS 対象および方法 PACS 結果 Mac OS
32 60 6 OS 考察 IP-VPN SSL/TLS VPN PC 1M 38 5 OS PACS 結論 OS
33 61 大学院修士論文要旨 Skyline view 小池正行 はじめに Skyline view X X 368 X 3D 2 目 的 4 Skyline view X 結 果 方 法 Skyline view X 1 64 CT D 考 察 DCT X Skyline view
34 62 Skyline view Skyline view 結論 Skyline view
35 63 大学院修士論文要旨 Computed Tomographic - Pancreatic Ductography CTPD CT 松崎 真也 はじめに Multi Detector-row CT MDCT MDCT endoscopic retrograde pancreatography ERCP magnetic resonance cholangiopancreatography MRCP Dynamic-CT 方法 64 CT Aquilion64 TOSHIBA Computed Tomographic Pancreatic Ductography CTPD 100ml 3ml/sec Duai shot, Japan CT 1mm Dynamic-CT 0.5mm region of interest ROI Zio station AMIN Japan 3D-CT 3D-CT 対 象 結 果 CT 40 : intraductal papillary-mucinous neoplasm PMN
36 CT 1 CT descending type 110 descending type loop type 1 bifid tail type 1 spiral type 0 main duct duplication type 0 diffused plexus type 0 ring-like duplication type 考察 CT Dynamic-CT CT ROI Dynamic-CT MRCP Ray-sum Ray-sum X Computed Tomographic - Pancreatic Ductography CTPD CTPD /112 ERCP MRCP CTPD CTPD 1 結論 MDCT MDCT CTPD CTPD
評価結果報告書の概要版(平成20年度)
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76
More informationuntitled
1 2 2 2 3 3 4 4 5 9 6 9 7 10 8 13 1 34 2 46 1 46 2 51 3 54 4 58 5 64 72 74 76 78 80 81 82 86 90 94 98 99 99 100 104 106 108 112 113 114 115 116 117 118 119 119 120 121 122 123 123 124 124 125 125 126 126
More information(1)〜(4)/松尾
kcalkcal SV SV SV BMI BMI SV SV SV kcal kcal kcal kcal SV SV kcal SV SV SV SVSV SV SV SV SVSV SV SV SV SV SV SV SV SV SV SV SV SV SV SV BMI BMI BMI BMI (ADL kcal SV SV SV SV SV BMI kcal kcal BMI
More information125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
More information次世代育成支援行動計画
15 7 10 300 9 17 21 5 21 22 5 1 2 3 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 16 39 40 11 2 3 P P 41 42 13 3 70.4 86.0 33.3 35.1 75.3 91.5 28.8 36.2 49.0 28.7 14.0 10.0
More informationA B 1.A B A B 2.A B A B 3.A
1 1. 2.WHO 3. 4. 5. 2 2.0mg/kg / 1. 2. 3. 4. 5. 3 1. 90 2. 3. 4. 5. 4 1. 2. 3. 4. 5. 1 21 5 1. 2. 2050 61 3. 1 4. 5. 6 1. ----------- 2. ---- 3. ------ 4. -------- 5. --------- 7 A B 1.A B------------------A
More information医療レーザー脱毛の威力と限界
.... mm. CT WH W H W H W H... kcalkcal. 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D. kg mm . CT WH W H W H W H... kcalkcal . 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D.
More information[] 1
0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2
More informationHOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu
More information% %
4 8 4 5 414.5 172.1 41.5% 39.8 10% 17 186.4 70.8 4 9 10 11 3 1-1 - 2-2 - - 3 - 10% - 4 - 4060% 5560% 60% 40% 3040 1520 1015 411 7 4 11 610 7080 5060 100 3040 13-5 - 1015 4045 3.04.0 5.06.0 1.52.0 1.01.5
More information2011 31th近畿学術集会 抄録
2 1 2 3 9:25-9:30 9:30-10:30 1,2) 1,2,3) 1)2)3) 1,2) 1,2,3) 1)2)3) 1,2,3) 1,2) 1)2)3) 10:30-10:40 10:40-11:50 1) 1) 1) 2) 1) 1) 1) 2) 1) 2) 1) 2) 1) 2) 4 1) 2) 2) 1) 2) 1) 1) 1) 1) 2) 1) 2) 11:50-13:10
More information56cm 1 15 1960 2 8 2 2 1 2008 1992 2 1992 2 3562mm 3773mm 2 1980 1991 2008 2007 2003 5 2 3 2003 2005 2008 2010 2005 2008 2012 2010 2012 4 7 4 5 2 1975 1994 8 2008 NPO 2 2010 3 2013 2016 3 2008 2009 14
More information障害者職域拡大カリキュラム研究会中間報告書構成案
3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16
More informationまえがき
JAAS0012006 1 -------------------------------------------------------------------------------------------------------- 1 2 --------------------------------------------------------------------------------------------------------
More informationQOL 02 QOL QOL UI AI EAThoracotomy TTThoracoscopy TS QOL EA type-c y score UI 3 AI 8 School score QOL score 12
54 1 2018 2 4-1 OK-432 1 15 14 15 US CT MRI 17 cm 0.16 g/kg/day OK-432 3 1 ke 2 2 ke 3 1 1,150 ml 13 US OK-432 4-2 TJ-28 TJ-28 2003 3 2017 6 250 TJ-28 44 16 28 TJ-28 7 2 46 8.5 2 2 9 34 79.1 10 23.3 34
More information無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
More informationエンジョイ北スポーツ
2772083130 83 1 2 3 4 5 6 7 8 2 2 2 3 3 4 4 6 7 8 1211 53 /15,171 /509 /670 /13,992 2 83130 http://www.kita-city-taikyo.or.jp 83130 http://www.kita-city-taikyo.or.jp 3 68 35 45 4 83130 http://www.kita-city-taikyo.or.jp
More information21 1 503604705 MRI CT 1 3 MRIMRS 5 5 5 5 5 6 7 8 17 1 17 2 17 3 17 4 18 5 19 21 1 23 2 1 27 3 2 48 4 3 88 5 105 6 110 7 118 MRS MRS ATP 312CT 65 60 1 2 1 1 1 2 1 2 2 X CT MRS 3 36657269 MRIMRS 1.5TMRSymphony
More information12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36
More information‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01
2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation
More informationMicrosoft Word - No.1武村.doc
1) 1) 1) 2) 2) 2) 1) 2) 23 31.15% 23.1% () 2009 4 2011 8 65 ( ) ( ) 2 BMI (FIM ) 89 45 44 83.48 8.55 (p=0.66) 87.11 5.53 (p=0.39) 19 26 9 35 (P
More information被曝二世健康影響調査
19 3 1 1. 3 2. 4 4 4 6 7 8 8 3. 10 10 10 11 12 4. 14 14 15 15 15 15 16 17 17 18 18 19 19 5. 20 6. 21 22 2000 7 5 4 6 4 77,000 5mGy 5mGy 24,673 57.3 84.5% 11,951 BMI 1 - 1Gy 0.91 1Gy 0.98-48.6 48.4 19 10
More information01-表紙から目次.PDF
56 100 1,205 45 11 30 48 56 56 10 56 1. 2 2. 2 3. 3 5 5 7 14 1 11 1. 11 (1) 11 (2) 11 (3) 11 (4) 12 (5) 12 2. 12 (1) 12 (2) 13 (3) 13 (4) 14 (5) 14 (6) 14 (7) 15 (8) 15 2 16 1. 16 (1) 16 (2) 17 (3) 17
More information外因性内分泌攪乱化学物質調査暫定マニュアル(水質、底質、水生生物)
N- 1) 2) 1) GC/MS HPLC GC/MS 2) 0.01~0.05µg/l 0.5~50µg/kg GC/MS SIM GC/MS SIM GC/MS SIM a) b) -d 10 -d 10 -d 12 -d 12 c) d) 600 C 4 e) 1 99.999% f) a) b) - IX-1 - c) (ODS) 200-1,000mg 5ml 5ml 5ml d) e)
More information2
1 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234 12123456789012345678901234
More information/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1
11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1
More informationC033** of 7 C034** PEG-IFN-2b + IFN -2b + 78 HCV-RNA PEG-IFN-2b IFN-2b n=250 n=200 n= =10 % % 85 % 74 % %
2.7.6.9 2.7.6.9.1 Genotype 1 C PEG-IFN-2b+ C033* Genotype 1 C PEG-IFN-2b + IFN-2b + 2.7.6-54 2.7.6-54 C033* 1 of 7 Genotype 1 C PEG-IFN-2b+ Genotype 1 C PEG-IFN-2b + IFN-2b + 24 HCV-RNA 48 24 follow-up
More informationMETs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV,
2002002 Guidelines for Exercise Eligibility at Schools, Work-Sites, and Sports in Patients with Heart Diseases (JCS 2003) JR 2 3 2 3 2 2 3 2 2 3 Circulation Journal Vol. 67, Suppl. IV, 2003 309 2002002
More information20-121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
More information1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
More information第1回地域理学療法学会_プログラム/抄録集_修正
2015 1 24 I-site URLhttp://01jcbpt.jimdo.com/ -site 2141 2 800m 12 5 1,000m 15 1 450m 7 1-B 450m 7 420m 6 1 1 1 26 4 1 1 1 75 1 1 1 I-site 2 915 5,000 2 3 2 1 20 10 2 10 1 9 6 3 5 6 2 PC Windows PC PowerPoint
More information中高齢者の健康・いきいきライフスタイルづくり調査
1 -- -- 10 11 12 1998-2000 Exercise: A Guide from the National Institute on Aging 1 61-80 26 T PHA Streptoccocal enterotoxin ASEA (IL-2; Th1 ) IL-4Th2 IgE T T - Bcl-2 Fas T PHA SEA IL2 T PHA SEA IL2
More informationuntitled
5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg
More information23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213
More information1 1 2 2 3 3 4 5 5 6 6 7 7 8 8 9 9 10 10. 11 1 12 1 13 2 13 3 8 13 4 14 5 14 6 14 7 15 8 15 1 17 2 22 3 24 4 24 1 33 2 42 1 49 2 50 3 50 4 56 1 60 2 88 3 93 1 95 2 96 1 98 2 100 1 100 2 104 3 105 4 105
More informationMicrosoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
More information橡マニュアル1999.PDF
11 11 7 28 7 30 9 30 16 30 2-302 1. (hardware) Microsoft Excel Microsoft Word Windows95/98 OS Windows95/98 MS-DOS 2. 3. 1 1 2 4. Enter CTRL ALT ALT SHIFT ESC BS DEL INS TAB CAPS 5. 1 ID ID 2 ID 3-1 - 6.Windows95/98
More informationuntitled
Ref. No: KiG14B23-Kokushi22-R01 22 1/23 Ans Ans 1 75 64 74 8 75 75 Ans 9 75.1 2010 Ans Ans 1000 Ans 85cm 90cm 25 130mmHg 85mmHg 100mg/dl HbA1c 5.6 HDL 150mg/dl HDL-C 40mg/dl 1 3 Ans 1 (): 2 (): 3 (): 4
More information10 44 1.2 5 4 5 3 6-1 - 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 TEL TEL 1 2 TEL FAX TEL FAX TEL FAX 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 ( ) ( ) 2
More informationuntitled
-1- -2- -4- -5- 20 30 12-6- 8 15 1-7- -8- -9- -10- 40 60-11- -12- 3 4 70 90-13- -14- 2 4 3 5-15- a 3-16- -17- -18- 128 kg 150 200g 100 200g 250 750g 2 1 94 89 89 81 72 390 97 97 83 83 75 97 97 100 86
More information<4D F736F F D2095BD90AC E93785F8C C9F8DB8926C82A982E782DD82BD89C193FC8ED282CC8C928D4E8FF391D482C98AD682B782E992B28DB895AA90CD2E646F6378>
29 7 IT 27 339 5,199 464 40-74 100cm 2 100cm 2 BMI25kg/m 2 85cm90cm 85cm90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL HbA1c
More informationuntitled
30803040 1015 1 2 3 4 5 6 60 7 8 [ ] [] [ ] / 9 10 [] [] [] / () 11 12 61 13 Borg 14 15 16 mm mm 17 () BMI 200mg/dl 18 Anderson 200mmHg 120mmHg 40mmHg 20mmHg 62 AED 19 20 () 21 22 23 24 63 25 26 27 28
More informationニトロトルエン
4-115 116 4-3 2 117 4- g/kg/day mg/kg/day 25 125 30 40 50 100 250 300 ( ) ( ) ( ) ( ) F1 42 10 118 ER 10-11 M 1% 10-11 10-4 M ER 10-4 M 3% 10-11 10-4 M E-screen 10-9 10-4 M AR ( ) 10-6 10-4 M AR ( ) 10-6
More information6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61
More information<82D282A982C1746F95F18D908F57967B95B E696E6464>
1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9
More information180 140 22
21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3
More information64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
More informationMicrosoft Word - 10_TKT_report02.docx
28 10:00-12:00 15:00-17:00 IC 29 30 2010 31 32 33 34 2 16 1/3 PTA 10 1/3 60 70 2 19:00 21:00 60 4 35 1986 6 150 1 10 1000 1 10 50 60 1 only 21 2 51 40 60 2 1 ex. 36 73 44 6 2011 80 13 5 8 60 30 80 1 54
More informationLDL HbA1c6. 5% AST51 ALT51 - GT LDL180 1, mmHg 85mmHg 150mg/dL HDL 40mg/dL 100mg/dL HbA1c 5.6% mmhg mg/dl mg/
30 7 IT 28 335 704 4 16 40-74 1 3 1100cm 2 100cm 2 BMI25kg/m 2 285cm 90cm 385cm 90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL
More information第 14 回血管病理研究会 日時 : 平成 20 年 10 月 10 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ) CRP MPO-ANCA 125IU/l CT mpa
第 4 回血管病理研究会 日時 : 平成 20 年 0 月 0 日 ( 土 ) 会場 : 佐賀大学医学部臨床大講堂 3208 号室会長 : 徳永藏 ( 佐賀大学医学部病因病態科学講座 ). 67 2008 CRP MPO-ANCA 25IU/l 009 2 CT mpa GCA PSL 50 mg CRP MPO-ANCA mpa GCA 4 mpa ovarlap 2 TLR 2 2. 対象 方法
More information平成17年度 マスターセンター補助事業
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - IC IC - 29 - IT
More information10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11
More information0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2
24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216
More informationuntitled
DiBartola SP DiBartola SP 1987 Elliott Elliott J 1998 Elliott J 2000 Elliott J 2003 Part 1 24 0.75 70 1.3 1.3 2.0 1/2 2 6 1/2 22 18 Part 2003 Dr Chew 1 2 2 3 Part Cre Cre 1 Part Cre 2% 0.1ml/kg 0.3ml/kg
More information後期化学_01_濃度
2011 ( ) 1 4 1 100 g g % * 1 100 g 1 g 1 % * 2 (1 g)/(100 g) = 0.01 = 1 % 100 g 100 g 99 g 100 g 1 g 1 % 2.5 g 50 g (2.5 g)/(50 g) = 0.050 = 5.0 % 100 ml g 1 %(w/w) wt% % %(w/v) % / 2 % SI 2 / % 100 ml
More informationエディロールカプセルインタビューフォーム
2012 4 5 873112 2008 () 1 0.5g 0.5g 0.75g 0.75g JAN EldecalcitolJAN 2011 1 21 2011 3 11 2011 4 11 TEL0120-591-818 03-3985-5599 8:3017:00 http://www.taishotoyama.co.jp/ 20124 http://www.info.pmda.go.jp/
More information緑化計画作成の手引き 26年4月版
http://www.city.shibuya.tokyo.jp/env/en_eventact/midori_ryokka.html 10 11 12 13 14 15 16 17 18 19 P10 P10 1 P12 2635 Fax (1) 47 03-5388-3554 http://www2.kankyo.metro.tokyo.jp/sizen/sinseisyo/e2/tebiki.htm
More information広報かみやま
http://www.town.kamiyama.lg.jp 新 町 議 会 議 員 紹 介 27121520 10 21 28 1 6 1 28 441826 2 35 NGUYEN THI TRANG 6814 28 10 2 2 4 336 3 25 CONG HUI LOVE EVERLY AIXI 1 2 1020 5 5 TEL05702001780570200291 TEL05707835780570064738
More information20 57
56 20 57 58 59 12 60 ph 61 62 CCA 63 64 ( 1) 700 7.5 86% 54 17 71 2) 700 6.8 86% 50 15 65 3) 600 700 5.7 84% 36 14 50 550 650 4.2 80% 21 6 27 40 500 3.6 78% 16 7 23 3.6 78% 16 7 23 400 700 4.0 78% 18 7
More informationGL_高野班_D.indd
Circulation Journal Vol. 72, Suppl. IV, 2008 1443 PCI CCU STEMI CABG ST ST1 EBM ST ST ST ST ST ST 1 EBMEvidence-Based Medicine 1444 Circulation Journal Vol. 72, Suppl. IV, 2008 ACS ST T ST CLBBB ST ACS
More information200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
More information5 10 10-1 - 5 20-2 - - 3 - - 4 - 22 6 30 10 12 22 7 8 1 30 4 30 1 22 7 14 10 12 20 22 7 21 1 30 3 30-5 - - 6 - - 7 - 11 9 9 14 10 9 15 7 9 10 NPO - 8 - - 15 - - 16 - - 17 - - 19 - - 20 - - 21 - - 22
More information奄美地域の自然資源の保全・活用に関する基本的な考え方(案)
1 15 5 15 16 19 20 2 3 10 25,000 30,000 6 8 710 11 16 4 1213 1415 17 17 28 17 126,483 30 5 70,462 8,572 27,167 14,551 5,731 29 18 560 10 1,032 1 6 1,300 47 28 4 19 1 8 23 17 100 7 15 8 NPO IT 1979 9 NPO
More information競技スポーツの科学研究 ~ アトランタ五輪を終えて ~ 新潟大学・山崎 健
1997 3 1998 12 sin cos 1997 3 1998 12 1997 3 1998 12 1997 3 1998 12 4 1997 3 1998 12 1964!? 100m 94 100m 100mH 10 100m 1964 1997 3 1998 12 1996 100m 7 0.174 0.14 9 84 1988 200m 25m 1986 1997 3 1998 12
More informationAD-5423_2
/ 2 /2.7 /CTD 8 8 II II 1 2 6 mg/ 6 mg/ HIV C 80 mmhg 3 1 3 80 mmhg 31 / 2 /2.7 /CTD 8 8 II II 1 2 3 23 32 / 2 /2.7 /CTD 2.7.3.3.1-28 123 2.7.3.3.1-2 8 1 2 3 2.7.3.3.1-3 2.7.3.3.1-48 2.7.3.3.1-5 40 5 7
More information<4D F736F F D C6E30385F A B B83932E444F43>
1,2,4-1,2,4-Trimethylbenzene Pseudocumene 1,3,5-1,3,5-Trimethylbenzene Mesitylene CH 3 CH 3 CH 3 CH 3 CH 3 CH 3 1,2,4-trimethylbenzene 1,3,5-trimethylbenzene CAS 95-63-6 CAS 108-67-8 C 9 H 12 C 9 H 12
More information消費データ付きアンケート作成マニュアル
... 3... 4... 4... 5... 6... 6... 7... 8... 9... 11... 15... 16... 18... 19... 22... 26... 26... 27... 27... 27... 28... 29... 30... 31... 35... 36... 37... 37... 38... 39... 40...41... 42... 43... 44...
More information消費データ付きアンケート作成マニュアル
... 3... 4... 4... 5... 6... 6... 7... 8... 9... 14... 16... 17... 20... 24... 24... 25... 25... 25... 26... 27... 28... 29... 33... 34... 35... 35... 36... 37... 38... 39... 40... 41... 42... 43... 44...
More information1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
More informationuntitled
ver. 3.3JT EVENING PRIMROSE EXTRACT 1 - PMS 1 2 1 4 Oenothera laciniata Oenothera striata Oenothera biennis Oenothera erythrosepala - 2 80 60 40 20 0 1. 2 3 PGGPAC 2. 3 4 ESR3.5 10 5 /g 4 3 1 Helicobacter
More information(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
More informationBMI BMI
() () 2 QOL () () QOL 11 6 14 20 13.9 20 BMI 12 70 40 11 6 14 20 13.9 20 BMI 12 70 40 57.1 100 ) 1 100 1 250 11 11 430 315 73.3 494 247 50.0 322 60 18.6 12 70 62 88.6 100 18 57.1 1 100 1 250 430 315 73.3
More informationWHO Library Cataloguing in Publication Data 2003, Wilkinson,Richard Marmot,Michael Social determinants of health SDH The social gradient Stress Early life Social exclusion Work Unemployment Social support
More informationuntitled
19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1
More information1 2010 10 Argus-eye 2 3 P14 12 5 1 4 1 P25 19 73 5 P25 1-5-3 36 40d 1 2 3 73 40d 23 5 1 73 3 RC 2010 17 5 P48 6 P65 2 7 P71 P48 2-4-3 1975-1 1975 (200
2010 Q&A 2011 10 21 ( ) 1 2010 10 Argus-eye 2 3 P14 12 5 1 4 1 P25 19 73 5 P25 1-5-3 36 40d 1 2 3 73 40d 23 5 1 73 3 RC 2010 17 5 P48 6 P65 2 7 P71 P48 2-4-3 1975-1 1975 (2004 ) P65 1/8 1/8 1/8 1/8 P71
More information<4D F736F F D208C C9F8DB8926C82A982E782DD82BD89C193FC8ED282CC8C928D4E8FF391D482C98AD682B782E992B28DB895AA90CD2E646F6378>
28 6 IT 26 1 326 4,499 433 40-74 100cm 2 100cm 2 BMI25kg/m 2 85cm90cm 85cm90cm BMI25kg/m 2 130mmHg 140mmHg 85mmHg 90mmHg 150mg/dL 300mg/dL HDL 39mg/dL 34mg/dL LDL 120mg/dL 140mg/dL 100mg/dL 126mg/dL HbA1c
More information肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
More information07.報文_及川ら-二校目.indd
8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006
More information29 IL-6 IL-6 PD PD MT PTOT PD Hoehn- Yahr 5 PT OT 40 5 MT MT UPDRS FIM CASMTCL FIM UPDRS 2 3 CAS MTCL MT PT OT PD
Jpn J Rehabil Med 2011 ; : 134.142 2010 9 11 IL- Myokine Myokine 1 IL 6 10 10 IL-6 40 20 40 60 IL-6 1.39 1.01 pg ml 20 2.23 1.71 pg ml 40 2.51 2.29 pg ml 60 0.63 0.59 pg ml 0.7 0.64 pg ml 0.72 0.55 pg
More information<836C83628367834A8374834692B2B895F18145706466>
1. 30 5 500 2 7 100 2 10 100 2007 4 1 7,200 6,800 7 NPO 1,200 1 12 15 2 1.5 0.5 30 2 24 5 27 16.8 28 2.3 10,500 / 3 3,800 117 2 3 6 6,000 1 1 1 2 2006 1 6, 000 + + 8 30 17 00 7.5 13 2 B2 2. 50 2 3 1 1
More information<4D F736F F D B BA908593B98AC782AB82E593E082CC88C091538AC7979D82C98AD682B782E992868AD495F18D908F912E646F63>
12 62 1800 14 3 11 14 4 14 4 30 ... 1... 1... 1... 2... 5... 6... 7... 10... 13... 18... 19 21 22 24 27 28 31 32 33... 34... 35... 37 2 1,650mm () H=2,500W=2,000 460m 750m 500m 42.1m 1.15m () 100% 80%
More information1 5 6 2 3 7 8 4 5 9 10 6 7 11 12 8 1 2 3 4 5 6 7 1989 25.0% 19901999 6 2000 15.0% 9 13 1 2 3 4 5 50 2 5180 45.0% 81 35.0%, 5.0% + +, 5.0% +, 1, 5 +, 3 14 10 0% 20% 40% 60% 80% 100% n=20 3 5 2 n=20 55.0%
More information生活設計と金融・保険に関する調査 VOL.6
Vol.6 1 1 8 1 2 2 1 5 2 5 3 3 5 5 3 5 6 6 7 5 9 68.7 11 4 287.4 332.8 12 14 1 14 14 14 15 16 16 18 20 21 2 23 3 25 4 27 27 29 29 5 30 1 32 1 32 91.8 32 34 2 36 91.4 36 38 41 1 41 62.6 33.5 41 43 2 45 70.7
More information表 1 入院時検査所見 11,500L 471 L 17.0 gdl.3 L ph 7.49 PaCO 37.8 mmhg PaO 67.4 mmhg HCO 3.6 meql B E 1. meql 141 meql K 3.9 meql Cl 108 meql Ca 8.4 mgdl P 4.5
Ⅰ. 臨床編 A. 特殊な病態における輸液 1 新生児 未熟児における輸液 実践編症例検討 症例の経過と実際の輸液療法 症例 ❶ 0 主訴 分娩歴 38 4,110 g.4 SD 47.5 cm0.5 SD 3.5 cm0.5 SD 8 1 9 5 現病歴 35 mgdl 60 0 mgdl 入院時現症 150 50 37. 503 mmhg SpO 98FiO 0.1 入院時検査所見 33 mgdl
More information第20回愛知県作業療法学会.indd
20 The 20 th Aichi Occupational Therapy Congress 24 513 20 2012 513 20 TEL0587513333FAX0587513300 INDEX 1 2 3 4 5 6 7 8 11 15 25 38 39 40 20 10 30 11 20 11 30 12 30 10 30 11 20 11 30 12 30 14 00 15 30
More information薬物動態解析ソフトを用いた 造影CT検査シミュレーション
CT CT CTA 1. 2. 3. 1. A), D), E) 4 Drug metabolism and Pharmacokinetics DMPK 1. 2. 3. 3 AUC C=Ae -ket ke MRT OGAWA V(ml) = 0.168H 3 0.05W 0.444 1000 H (m) W (kg) V(ml) = 0.250H 3 0.063W 0.662
More informationuntitled
) 56 71 71 71 SI 135 62 71 103 85 64 27 49 133 55 89 59 50 57 75 23 76 59 55 71 47 55 168 57 103 50 50 104 68 88 73 168 56 47 71 80 55 75 67 46 59 62 55 100 47 76 174 46 50 85 15 5 15 0 5 0 SI Spectrum
More informationml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G
More informationMicrosoft Word - 観光と食 2・3 食品添加物 vs. 質の事業.doc
2 1. Ø 90 15 100 130 3 Ø Ø Ø Ø Ø ph Ø Ø ph Ø Na Na CMC OKINAWA UNIVERSITY 1/13 Na Na V.C ph ph Ø C g mg Ø ml g Ø Ø V.C g C mg 50kcal g Ø OKINAWA UNIVERSITY 2/13 Ø Ø Na Ø Ø Ø Ø Ø Ø Ø 1. 2. 3. 4. Ø OKINAWA
More informationuntitled
20073-1- 3 4 5 9 12 14 17-2- 3,700ha 30,000t -3- 1t 70 50 40 C/N -4- 20011228 C/N 13 2001 2cm 1t 60 70 60-5- 70 1t -6- 2003131 ph EC T-C T-N C/N P2O5 K2O CaO MgO HO 2 ms % % % % % % % 8.52 0.64 74.9 44.9
More information1. 1,,,,,,, TUR-P, TUR-Bt 2 3 TUR P,TUR-Bt 4 2, 3. [ ] 1 2,,, 2
2010 1. 2. 3. 4. 5. 6. 7. 7. 8. 1 1. 1,,,,,,, TUR-P, TUR-Bt 2 3 TUR P,TUR-Bt 4 2, 3. [ ] 1 2,,, 2 2,,,,,, NYHA,,,,, Hugh-Jones,,,,,,,,,,, 10 / l PT-INR1.5 APTT 50 NSAIDs 4 1 12 24 12 5PT-INR PT INR 3
More informationCTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
More information橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
More informationuntitled
er. 3.0SJ ver.3.0 SJ 3 2 1 ver.3.0 SJ 900 1200 () 400 2 ver.3.0 SJ OH OMe OMe O O O MeO O MeO OMe O O OMe O OMe OMe O O MeO O O H O O MeO OMe O H O OH OMe O CH 2 HO O O O O CH 3 OH HO OH OH HO OH O 1 3
More information